CN105693812A - 刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 - Google Patents
刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 Download PDFInfo
- Publication number
- CN105693812A CN105693812A CN201610055397.3A CN201610055397A CN105693812A CN 105693812 A CN105693812 A CN 105693812A CN 201610055397 A CN201610055397 A CN 201610055397A CN 105693812 A CN105693812 A CN 105693812A
- Authority
- CN
- China
- Prior art keywords
- echinocystic acid
- cancer cells
- echinocystic
- cell
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MCHWKJRTMPIHRA-UHFFFAOYSA-N n-(pyrrolidin-2-ylmethyl)aniline Chemical class C1CCNC1CNC1=CC=CC=C1 MCHWKJRTMPIHRA-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims description 12
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title description 14
- YKOPWPOFWMYZJZ-FMMUPTMQSA-N Echinocystic acid Natural products C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YKOPWPOFWMYZJZ-FMMUPTMQSA-N 0.000 claims abstract description 53
- YKOPWPOFWMYZJZ-UHFFFAOYSA-N Echinocystsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C YKOPWPOFWMYZJZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 4
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 4
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 241001597008 Nomeidae Species 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 17
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 241000931143 Gleditsia sinensis Species 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 150000002611 lead compounds Chemical class 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000012043 crude product Substances 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 230000006837 decompression Effects 0.000 description 9
- 239000003292 glue Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- 229910052710 silicon Inorganic materials 0.000 description 9
- 239000010703 silicon Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 echinocystic acid compound Chemical class 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000533849 Gleditsia Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
- QGXMHCMPIAYMGT-UHFFFAOYSA-N 2-phenylbutanoyl chloride Chemical compound CCC(C(Cl)=O)C1=CC=CC=C1 QGXMHCMPIAYMGT-UHFFFAOYSA-N 0.000 description 1
- ZJIOBDJEKDUUCI-UHFFFAOYSA-N 3,5-dimethylbenzoyl chloride Chemical compound CC1=CC(C)=CC(C(Cl)=O)=C1 ZJIOBDJEKDUUCI-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- OKHSVCZDYHBEKX-UHFFFAOYSA-N formyl chloride toluene Chemical compound C(=O)Cl.CC1=CC=CC=C1 OKHSVCZDYHBEKX-UHFFFAOYSA-N 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610055397.3A CN105693812B (zh) | 2016-01-28 | 2016-01-28 | 刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610055397.3A CN105693812B (zh) | 2016-01-28 | 2016-01-28 | 刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105693812A true CN105693812A (zh) | 2016-06-22 |
CN105693812B CN105693812B (zh) | 2017-05-24 |
Family
ID=56228671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610055397.3A Expired - Fee Related CN105693812B (zh) | 2016-01-28 | 2016-01-28 | 刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105693812B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109206470A (zh) * | 2018-08-28 | 2019-01-15 | 吉林省中医药科学院(吉林省中医药科学院第临床医院) | 刺囊酸衍生物制备方法及医药新用途 |
CN112915096A (zh) * | 2016-07-06 | 2021-06-08 | 天津中医药大学 | 刺囊酸-28-O-β-D-葡萄糖苷的用途以及包含其的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001684A2 (en) * | 2005-05-19 | 2007-01-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
CN101919901A (zh) * | 2009-06-10 | 2010-12-22 | 赵全成 | 皂角总苷元及刺囊酸在制备α-葡萄糖苷酶抑制剂的药物中的应用 |
-
2016
- 2016-01-28 CN CN201610055397.3A patent/CN105693812B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001684A2 (en) * | 2005-05-19 | 2007-01-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
CN101919901A (zh) * | 2009-06-10 | 2010-12-22 | 赵全成 | 皂角总苷元及刺囊酸在制备α-葡萄糖苷酶抑制剂的药物中的应用 |
Non-Patent Citations (2)
Title |
---|
JOSEPH H. REIBENSPIES ET AL.: "Crystal and molecular structure of echinocystic acid diacetate,a secondary metabolite isolated from Cucurbita faetidissima H.B.K.", 《JOURNAL OF CRYSTALLOGRAPHIC AND SPECTROSCOPIC RESEARCH》 * |
MAITÉ RODRÍGUEZ-DÍAZ, ET AL.: "Topical anti-inflammatory activity of quillaic acid from Quillaja saponaria Mol. and some derivatives", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112915096A (zh) * | 2016-07-06 | 2021-06-08 | 天津中医药大学 | 刺囊酸-28-O-β-D-葡萄糖苷的用途以及包含其的药物组合物 |
CN109206470A (zh) * | 2018-08-28 | 2019-01-15 | 吉林省中医药科学院(吉林省中医药科学院第临床医院) | 刺囊酸衍生物制备方法及医药新用途 |
CN109206470B (zh) * | 2018-08-28 | 2020-12-11 | 吉林省中医药科学院(吉林省中医药科学院第一临床医院) | 刺囊酸衍生物制备方法及医药新用途 |
Also Published As
Publication number | Publication date |
---|---|
CN105693812B (zh) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102675403B (zh) | 抗乙肝药物lqc-x的合成及其应用 | |
CN102127142B (zh) | 救必应酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN104341430A (zh) | 一种土甘草a及其提取方法和用途 | |
CN102940687B (zh) | 一种川楝子提取物及其用途 | |
CN102030796A (zh) | 从夹竹桃中分离出的几种强心苷化合物及其应用 | |
CN105693812A (zh) | 刺囊酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN105859823A (zh) | 救必应酸酯类衍生物在制备抗肿瘤药物中的应用 | |
CN104892713A (zh) | 葫芦素c及其类似物的制备方法与应用 | |
CN102267891B (zh) | 一种三萜化合物及其制备方法 | |
CN103833823B (zh) | 二萜二聚体类化合物及其药物组合物和制备方法与应用 | |
CN101156882B (zh) | 三七原人参二醇型皂苷制备方法 | |
CN106317155B (zh) | 一种还原性葫芦烷型三萜及其制法和用途 | |
CN103610682B (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
CN109879921A (zh) | 从知母中分离的具有抗肿瘤活性的化合物及其制备方法 | |
CN102993018B (zh) | 一种5-硝基咖啡酸金刚醇酯及其在制备抗肿瘤药物中的应用 | |
CN106317157B (zh) | 一种多羟基双酮类葫芦烷型三萜及其制法和用途 | |
CN105418722B (zh) | 一种名为油茶皂苷c4和c5的五环三萜类化合物的制备方法 | |
WO2016107471A1 (zh) | 一种stat3、erk信号通路抑制剂及其应用 | |
CN105079011A (zh) | 一种具有抗肿瘤作用的药物的制备和应用 | |
CN104274429B (zh) | 环阿尔廷型三萜化合物在制备抗肺癌药物中的应用 | |
CN103006670B (zh) | 一种总不饱和蟾蜍内酯及其制备方法和用途 | |
CN101774921A (zh) | 二咖啡酰奎尼酸类甲酯化合物的制备方法及其组合物 | |
CN110063960A (zh) | 3-氢化松苓酸b氰甲酯的制药用途 | |
CN105560261B (zh) | 知母皂苷n在制备防治糖尿病药物中的应用 | |
CN103948604A (zh) | 常春藤皂苷元类化合物作为治疗肝癌药品的应用及其制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Nan minlun Inventor after: Heyufang Inventor after: Wang Xue Inventor after: Zhao Yuwei Inventor after: He Zhongmei Inventor after: Zhao Quancheng Inventor before: Nan minlun Inventor before: Zhao Yuwei Inventor before: Heyufang Inventor before: Lv Na Inventor before: He Zhongmei Inventor before: Zhao Quancheng |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170524 |
|
CF01 | Termination of patent right due to non-payment of annual fee |